OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration
LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs...